{"id":"infergen-and-ribavirin","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"10-15","effect":"Hemolytic anemia"},{"rate":"5-10","effect":"Neutropenia"},{"rate":"5-10","effect":"Thrombocytopenia"},{"rate":"5-15","effect":"Depression and psychiatric effects"},{"rate":"5-10","effect":"Thyroid dysfunction"},{"rate":"20-30","effect":"Headache"},{"rate":"10-20","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Infergen is a recombinant type I interferon that binds to interferon-alpha receptors on cell surfaces, triggering antiviral and immunomodulatory pathways including activation of natural killer cells and upregulation of MHC molecules. Ribavirin is a guanosine analog that inhibits viral RNA-dependent RNA polymerase and depletes cellular guanosine triphosphate pools, reducing viral replication. Together, they provide complementary antiviral mechanisms for treating chronic hepatitis C.","oneSentence":"Infergen (interferon alfacon-1) is a synthetic interferon that activates innate immune responses to inhibit viral replication, while ribavirin is a nucleoside analog that directly inhibits viral RNA synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:33:21.822Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection"}]},"trialDetails":[{"nctId":"NCT00086541","phase":"PHASE3","title":"Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2004-06","conditions":"Chronic Hepatitis C","enrollment":515},{"nctId":"NCT01903278","phase":"PHASE3","title":"Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C","status":"COMPLETED","sponsor":"Beijing Kawin Technology Share-Holding Co., Ltd.","startDate":"2013-06","conditions":"Chronic Hepatitis c","enrollment":719},{"nctId":"NCT00951223","phase":"","title":"Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C","status":"WITHDRAWN","sponsor":"Kadmon Corporation, LLC","startDate":"2009-08","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT00211692","phase":"PHASE3","title":"Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial","status":"COMPLETED","sponsor":"Minneapolis Veterans Affairs Medical Center","startDate":"2005-07","conditions":"Chronic Hepatitis C","enrollment":64},{"nctId":"NCT01908335","phase":"PHASE2","title":"A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Beijing Kawin Technology Share-Holding Co., Ltd.","startDate":"2012-10","conditions":"Chronic Hepatitis C","enrollment":212},{"nctId":"NCT00239252","phase":"PHASE3","title":"Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT00456248","phase":"PHASE4","title":"Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin","status":"TERMINATED","sponsor":"Kadmon Corporation, LLC","startDate":"2007-02","conditions":"Hepatitis C","enrollment":5},{"nctId":"NCT00162734","phase":"PHASE3","title":"Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2005-02","conditions":"Chronic Hepatitis C","enrollment":144},{"nctId":"NCT00207402","phase":"PHASE4","title":"Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin","status":"COMPLETED","sponsor":"Brooke Army Medical Center","startDate":"2005-10","conditions":"Hepatitis C","enrollment":34},{"nctId":"NCT00084279","phase":"PHASE2","title":"CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)","status":"COMPLETED","sponsor":"InterMune","startDate":"2004-04","conditions":"Chronic Hepatitis C","enrollment":81},{"nctId":"NCT00266318","phase":"PHASE4","title":"Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy","status":"COMPLETED","sponsor":"Beth Israel Medical Center","startDate":"2005-12","conditions":"Hepatitis C","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Infergen and ribavirin","genericName":"Infergen and ribavirin","companyName":"Kadmon Corporation, LLC","companyId":"kadmon-corporation-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Infergen (interferon alfacon-1) is a synthetic interferon that activates innate immune responses to inhibit viral replication, while ribavirin is a nucleoside analog that directly inhibits viral RNA synthesis. Used for Chronic hepatitis C virus infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}